Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors have significantly improved the outcomes of head-and-neck squamous cell carcinoma (SCC). However, predictive biomarkers for response remain limited, especially in tumors with low programmed death-ligand 1 (PD-L1) expression. We report the case of a 47-year-old man with SCC of the tongue who exhibited a low PD-L1 combined positive score (CPS < 1). The patient developed local recurrence 5 months after surgery and adjuvant radiotherapy. The patient achieved complete response following chemotherapy with pembrolizumab and remained disease-free after 2 years of maintenance therapy. This case emphasizes the potential durable response to pembrolizumab in patients with oral SCC with a low CPS and raises major considerations regarding immunotherapy duration.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: